Table 2.
Pathologic, oncologic, and surgical outcomes for patients with gastroesophageal junction adenocarcinoma in unmatched and matched cohorts
| Unmatched cohort | Matched cohort | ||||||
|---|---|---|---|---|---|---|---|
| Esophagectomy (n = 999) n (%) | Gastrectomy (n = 8595) n (%) | p Value | Esophagectomy (n = 999) n (%) | Gastrectomy (n = 3868) n (%) | p Value | ||
| Tumor grade | Well | 69 (6.9) | 626 (7.3) | 0.8 | 69 (6.9) | 300 (7.8) | 0.8 |
| Moderate | 402 (40.2) | 3363 (39.1) | 402 (40.2) | 1534 (39.7) | |||
| Poor | 412 (41.2) | 3660 (42.6) | 412 (41.2) | 1588 (41.1) | |||
| Anaplastic | 116 (11.6) | 946 (11.0) | 116 (11.6) | 446 (11.5) | |||
| AJCC pathologic T stage | pT0 | 164 (16.4) | 818 (9.5) | <0.001 | 164 (16.4) | 438 (11.3) | <0.001 |
| pT1 | 376 (37.6) | 2195 (25.5) | 376 (37.6) | 1089 (28.2) | |||
| pT2 | 121 (12.1) | 1321 (15.4) | 121 (12.1) | 605 (15.6) | |||
| pT3 | 249 (24.9) | 3278 (38.1) | 249 (24.9) | 1398 (36.1) | |||
| pT4 | 1 (0.1) | 333 (3.9) | 1 (0.1) | 86 (2.2) | |||
| pTx | 88 (8.8) | 650 (7.6) | 88 (8.8) | 252 (6.5) | |||
| AJCC pathologic N stage | pN0 | 638 (63.9) | 4518 (52.6) | <0.001 | 638 (63.9) | 2202 (56.9) | <0.001 |
| pN1 | 179 (17.9) | 1647 (19.2) | 179 (17.9) | 728 (18.8) | |||
| pN2 | 75 (7.5) | 1110 (12.9) | 75 (7.5) | 463 (12.0) | |||
| pN3 | 27 (2.7) | 693 (8.1) | 27 (2.7) | 235 (6.1) | |||
| pNx | 80 (8.0) | 627 (7.3) | 80 (8.0) | 240 (6.2) | |||
| AJCC pathologic overall stage | Stage 0 | 230 (23.0) | 1327 (15.4) | <0.001 | 230 (23.0) | 624 (16.1) | <0.001 |
| Stage I | 389 (38.9) | 2631 (30.6) | 389 (38.9) | 1289 (33.3) | |||
| Stage II | 99 (9.9) | 1187 (13.8) | 99 (9.9) | 529 (13.7) | |||
| Stage III | 281 (28.1) | 3450 (40.1) | 281 (28.1) | 1426 (36.9) | |||
| Regional nodes examined | Median (IQR) | 14.0 (13.0) | 14.0 (13.0) | 0.6 | 14.0 (13.0) | 15.0 (12.0) | 0.3 |
| Margin status | Positive | 58 (5.8) | 995 (11.6) | <0.001 | 58 (5.8) | 358 (9.3) | 0.001 |
| Negative | 941 (94.2) | 7600 (88.4) | 941 (94.2) | 3510 (90.7) | |||
| Lymphovascular Invasion | Absent | 573 (57.4) | 4574 (53.2) | <0.001 | 573 (57.4) | 2137 (55.2) | <0.001 |
| Present | 146 (14.6) | 2104 (24.5) | 146 (14.6) | 844 (21.8) | |||
| Unknown | 280 (28.0) | 1917 (22.3) | 280 (28.0) | 887 (22.9) | |||
| Length of stay | Median (IQR) | 9.0 (7.0) | 9.0 (7.0) | 0.7 | 9.0 (7.0) | 9.0 (7.0) | 0.4 |
| 30-Day mortality | No | 977 (97.8) | 8333 (97.0) | 0.2 | 977 (97.8) | 3774 (97.6) | 0.8 |
| Yes | 22 (2.2) | 262 (3.0) | 22 (2.2) | 94 (2.4) | |||
| 90-Day mortality | No | 953 (95.4) | 8037 (93.5) | 0.024 | 953 (95.4) | 3663 (94.7) | 0.4 |
| Yes | 46 (4.6) | 558 (6.5) | 46 (4.6) | 205 (5.3) | |||
| 30-Day readmission | No | 917 (92.0) | 7934 (92.5) | 0.8 | 919 (92.0) | 3565 (92.2) | 0.7 |
| Yes - unplanned | 14 (1.4) | 107 (1.2) | 14 (1.4) | 42 (1.1) | |||
| Yes - planned | 66 (6.6) | 539 (6.3) | 66 (6.6) | 261 (6.7) | |||
AJCC, American Joint Committee on Cancer